Partner Article
Aesica to concentrate investment in lucrative German formulations business
Aesica Pharmaceuticals, which operates North East bases in Newcastle and Cramlington, says it is investing in its German operations in Zwickau.
The developer and manufactuer of pharmaceuticals is adding new roller compaction technology to the plant after identifying it as a key growth market within Germany.
Aesica has also recently invested in a tablet coating and pouch packing line facilties in the region.
Ian Muir, managing director, Finished Dose at Aesica commented: “This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, whilst allowing us to offer new services to our global customers.
“The dry granulation capability will drive business growth as customers with moisture sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products.”
This was posted in Bdaily's Members' News section by Tom Keighley .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution
Construction must be built on commercial discipline